阿加曲班治疗椎基底动脉系统进展型脑梗死的临床观察  

Clinical observation of argatroban in treatment of progressive cerebral infarction of vertebrobasilar artery system

作　　者：张颖[1] 刘晓丽[2] 

机构地区：[1]铁岭卫生职业学院,辽宁铁岭112000 [2]辽宁省铁岭市中心医院,辽宁铁岭112000

出　　处：《中国医药科学》2013年第19期85-86,99,共3页China Medicine And Pharmacy

摘　　要：目的观察阿加曲班治疗椎基底动脉系统进展型脑梗死的疗效及安全性。方法将椎基底动脉系统进展型脑梗死的住院患者298例随机分为治疗组(n=150)和对照组(n=148),治疗组给予阿加曲班及常规治疗,对照组予疏血通及常规治疗。于治疗前及治疗后7d、14d按照美国国立卫生研究院卒中量表(NIHSS)进行神经功能缺损程度评定并记录不良反应。结果与治疗前相比,治疗后14d两组NIHSS评分均下降,治疗组:(13.8±3.3)VS(5.1±1.6)(P<0.05);对照组:(13.3±2.9)VS(5.9±1.9)(P<0.05),治疗组疗效优于对照组(P<0.01)。两组均无明显不良反应。结论阿加曲班可明显改善椎基底动脉系统进展型脑梗死所致的神经功能缺损,改善远期预后,安全性良好。Objective To observe the efficacy and safety of argatroban in treatment of progressive cerebral infarction of vertebrobasilar artery system. Methods 298 hospitalized patients with progressive cerebral infarction of vertebrobasilar artery system were randomly divided into treatment group（n=150） and control group（n=148）. The treatment group was given argatroban and routine treatment, while the control group was received Shuxuetong injection and routine treatment. The neural function defected degrees were assessed by National Institutes of Health Stroke Scale（NIHSS） before treatment and at 7 days, 14 days after treatment, and adverse reactions were recorded, Results Compared with those before treatment, the NIHSS score of two groups at 14 days after treatment decreased, the NIHSS score of the treatment group： （13.8± 3.3） VS （5.1±1.6）（P 〈 0.05）; the control group： （13.3 ± 2.9） VS （5.9±1.9）（P 〈 0.05）. The effect in the treatment group was better than that in the control group（P 〈 0.01）. Two groups had no obviously adverse reactions. Conclusion Argatroban can obviously improve the neural function defect caused by progressive cerebral infarction of vertebrobasilar artery system, improve the long-term prognosis of patients, and has good safety.

关 键 词：进展型脑梗死 椎基底动脉系统 阿加曲班 

分 类 号：R453.9[医药卫生—治疗学]